PrEP - Pre-exposure prophylaxis
Aug 2, 2022
Article and Study Summary: Efficiency of 6-month PrEP dispensing with HIV self-testing in Kenya: an open-label, randomised, non-inferiority, implementation trial Published in: Lancet HIV. 2022;9(7):e464-e473 https://doi.org/10.1016/S2352-3018(22)00126-6 Authors: Ngure...
Jul 6, 2022
Article and Study Summary: Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial Published in: Lancet. 2022;399(10337):1779-1789 https://doi.org/10.1016/S0140-6736(22)00538-4 Authors: Delany-Moretlwe S, Hughes...
Jun 9, 2022
The novel coronavirus disease COVID-19 caused by SARS-CoV-2 threatens to disrupt global progress toward HIV epidemic control. Opportunities exist to leverage ongoing public health responses to mitigate the impacts of COVID-19 on HIV services, and novel approaches to...
Mar 10, 2022
Authors: S Bergam, A D Harrison, N Benghu, S Khumalo, N Tesfay, T Exner, L Miller, C Dolezal, J Hanass-Hancock, S Hoffman Daily oral pre-exposure prophylaxis (PrEP) offers effective HIV prevention. In South Africa, PrEP is publicly available, but use among young women...
Sep 28, 2021
Article and Study Summary: Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. Published in: N Engl J Med 2021;385(7):595-608. https://www.nejm.org/doi/full/10.1056/NEJMoa2101016 Authors: Landovitz RJ, Donnell D, Clement ME, et al. Summary: The HIV...